Welcome to lecture 2 in our Systems Medicine lecture notes. The purpose of this course is to study general principles of tissues, discover the regulatory circuits that are essential for health, and why these circuits fail in diseases. At the end of the course, I hope you will be able to ask questions about human physiology and disease and answer them with appropriate mathematical models.

We now enter Part 1 of the course, principles of hormone circuits. In this lecture and the next, we will focus on the ‘hydrogen atom’ of physiological circuits: the glucose-insulin control circuit. When I say hydrogen atom, I mean the simplest and best-understood system which provides the conceptual tools to understand more complex cases, just as hydrogen was the testing ground for quantum mechanics. The glucose circuit is a good starting point because it highlights several important principles that apply to many other tissues. It is also important medically, because its failure is the basis for diabetes, a disease afflicting about 10% of the world’s population (of which 90% is type-2 and 10% type-1 diabetes, see below).

Glucose concentration and dynamics is tightly controlled

The main variable in this system is the blood concentration of the sugar glucose. Glucose is an important energy and carbon source for the cells in our body. It is the major energy source for the brain. Glucose concentration in the blood is maintained within a tight range around 5mM: different healthy people have a concentration of 5+/−1mM.

This tight control is important. It is called homeostasis in biology - the ability of the body to keep important variables within a tight range. If glucose drops below 3mM, the brain does not have enough energy and we can faint. Prolonged low glucose, called hypoglycemia, can be fatal. The body switches to alternative energy sources such as ketone bodies which can cause blood acidity which is potentially lethal. Similarly, if glucose is too high, above 10-15mM, it damages blood vessels and nerves, and over the years gives rise to the deadly symptoms of type 2 diabetes. The damaged blood vessels can give rise to heart attacks, to kidney diseases and, in the retina, to blindness. Damaged blood vessels can also lead to amputation of legs and other grim outcomes.

*deep sigh of relief*

In addition to the tight control over the steady-state level of glucose, the entire glucose dynamics after a meal is tightly regulated. These dynamics are measured, for example, in a clinical test for diabetes, called the glucose tolerance test (GTT). In GTT, you drink 75g of glucose, and measure blood glucose in the following two hours. Glucose rises to about twice its basal level of 5mM, and then falls back to baseline in about 2 hours (Fig 2.1). Different healthy people have similar glucose
dynamics in the GTT. Aberrant dynamics are a sign of diabetes: glucose above 11mM at 2 hours is a clinical criterion for diabetes (Fig 2.2).

Glucose concentration is controlled by insulin

How is this tight control of blood glucose concentration achieved? The answer is a feedback circuit involving the hormone insulin, a small protein that is found in the blood. Insulin allows glucose to enter cells in muscle, liver and fat, and glucose is thus removed from the blood. Glucose is unable to enter these cells without special glucose transporters on their surface. The transporters are in storage vesicles inside the cell (Fig 2.3a). When insulin is in the blood, it binds special sensors on the cell surface called insulin receptors (Fig 2.3b), which bind insulin like a lock and key. When bound, the receptors initiate signaling pathways inside the cell that move the glucose transporters to the cell surface (Fig 2.3b), where they pump glucose into the cell. As a result, insulin binding allows glucose to enter the cell (Fig 2.3c).

Insulin is secreted by special cells in the pancreas called beta-cells. The pancreas is a thin gland about the size of a dollar bill located in our upper abdomen. In this gland are a million groups of cells called islets of Langerhans, each with about a thousand beta cells (Fig 2.4). The Islets also house other types of cells, like alpha cells that secrete glucagon, a hormone that acts to increase glucose production in the liver, which we will ignore for now. In general, we ignore many details that are not crucial for the principles we wish to describe.
The beta cells sense glucose, and the more glucose around, the more insulin they secrete. Thus, a rise in glucose leads to insulin secreted to the blood. Insulin induces cells in the muscle and fat to take up glucose, and so blood glucose levels drop. This is a negative feedback loop: more glucose, more insulin, and thus less glucose (Fig 2.5). The input to the blood glucose comes from meals, and from the production of glucose by the liver from other nutrients. We denote these sources by m in Fig 2.5.

**Diabetes is a malfunction in this system.** In type-1 diabetes (T1D), the immune system attacks beta cells, and kills them off. As a result, there is no insulin and cells cannot obtain the glucose they need. To survive, T1D patients rely on insulin injections. Until the 1930s' type-1 diabetes was a death sentence to about 1% of the children who got it (typical age of onset is 10-11). With the discovery of insulin, those children could survive thanks to insulin injections. Still, keeping glucose under control is hard, and type 1 diabetes raises the risk for health complications.

In type-2 diabetes (T2D), beta cells do not secrete enough insulin to remove blood glucose effectively. Glucose rises and over the years causes damage to the body. A major cause of type-2 diabetes is insulin resistance, which we will describe in detail below.

We have now completed the verbal introduction to this system. It is a basic version of the more intricate verbal description generally taught to doctors and biologists. The verbal description is powerful in that it can explain intuitively the dynamics, such as the rise and fall after a GTT, and the basic phenomena in diabetes.

*Song: Tangled up in glucose*

In this course we want to go beyond verbal descriptions and to write equations. Equations can help us focus on important parameters, and to generalize principles from one system to other systems. Most importantly, **equations help us to ask new questions**, such as what is the fundamental origin of diseases such as T1D and T2D. In this chapter we lay the foundations for the next two chapters in which we will make progress on these questions.

**Mathematical models for the glucose-insulin circuit**

In the glucose-insulin system, mathematical models developed since the 1970’s have had important benefits for clinical practice, because they helped to define important parameters like insulin resistance. They also provide practical ways to estimate these parameters for each patient based on clinical measurements. One important model is the minimal model by Richard Bergman (1979), and we will use a version of this model as a basis for our exploration.

In order to model the dynamics of the system, we use differential equations to describe rates of change of glucose and insulin concentrations in the blood. Blood glucose concentration, G(t), is supplied in two ways: the first is when we eat a meal and glucose enters the blood from the intestinal system. The second way occurs between meals, such as during fasting and sleep.
Glucose is then produced by the liver, which stores glucose in times of plenty in a polymer called glycogen, and breaks it down when we fast.

Summing over these two sources, we have the glucose supply \( m(t) \). Glucose is removed by the action of insulin. Thus, the rate of change of glucose, \( dG/dt \), is the sum of supply \( m \) minus removal

\[
(1) \quad \frac{dG}{dt} = m - aG
\]

Let’s focus on removal term \( aG \). The rate parameter \( a \) is the probability per unit time to lose a glucose molecule from the blood. For example, suppose we start with glucose concentration of \( G=G_0=5\text{mM} \), and then totally stop production, \( m=0 \). As a result, glucose is only removed,

\[
(2) \quad \frac{dG}{dt} = -aG
\]

The solution of this equation is an exponentially decaying concentration which drops over time from its initial level \( G_0 \) (Fig 2.6):

\[
(3) \quad G(t) = G(0) \exp(-at)
\]

The half-life of glucose is the time it takes to go halfway down from its initial level. This half-life, \( t_{1/2} \), is when \( G(t_{1/2}) = G_0/2 \). Plugging this into equation (3), we find \( \exp(-a t_{1/2}) = 1/2 \), and thus

\[
(4) \quad t_{1/2} = \ln(2)/a
\]

This is a general result: the half-life of a molecule is inversely related to its removal rate (faster removal leads to shorter half-life).

In our system, removal is due to insulin, so that \( a = sI \). The parameter \( s \) is called insulin sensitivity—an important parameter. Insulin sensitivity is the effect of a unit of insulin on glucose removal rate. It can be measured by injecting insulin and noting the reduction in glucose. Thus, our glucose equation is:

\[
(5) \quad \frac{dG}{dt} = m - sI G
\]

Now let’s write the equation for the rate of change of insulin concentration in the blood, \( I(t) \). Insulin is produced by beta cells, and the production rate rises with glucose. Thus, each beta cell makes \( q f(G) \) units of insulin concentration per unit time, where \( q \) is the maximal production rate per cell and \( f(G) \) is an increasing function of \( G \), that goes between 0 and one. As in many biological circuits, \( f(G) \) is well described by a Hill function,

\[
(6) \quad f(G) = \frac{G^n}{K^n + G^n}
\]

which reaches halfway to one at a glucose concentration of \( G=K \). The slope of this function is higher the larger the parameter \( n \). For beta cells, \( n = 2 \) is a good approximation, so that \( f(G) \) has a sigmoidal shape Fig 2.7.
Note that insulin is secreted into the blood. The more blood, the more insulin is diluted. Thus, the secretion rate parameter $q$ is the total number of molecules of insulin secreted per unit time, divided by the total blood volume, in order to get units of insulin concentration. All that we need to do now is to multiply the production rate per cell by the number of beta-cells $B$, to get a total insulin production of $qBf(G)$. Insulin is removed at rate $\gamma$, so that

$$\frac{dI}{dt} = qBf(G) - \gamma I$$

The removal parameter $\gamma$ provides the insulin half-life in the body, of about $\ln(2)/\gamma = 30 \text{ min}$. Insulin is removed primarily by degradation in the liver and secretion by the kidneys into the urine.

We now have the minimal model equations. Let’s see how they do in the glucose tolerance test. We can solve the equations on the computer, and provide a pulse of input glucose $m(t)$ to describe the glucose going into the body when we drink 75g of glucose solution. As a result, $G(t)$ first rises, and as a result insulin $I(t)$ rises, increasing the removal rate of $G$ until it returns to baseline (Fig 2.8). This resembles the measured response of healthy people.

*Pair and share. Math people form alliances with bio people.*

Let’s now ask about the tightness of glucose regulation. For example, is it plausible that $G_{\text{st}}$ and the dynamics $G(t)$ is so constant between people? The parameter to watch is insulin sensitivity, $s$. Insulin sensitivity varies between people: it is a physiological knob that allows the body to allocate glucose resources and determine which tissues get the glucose. For example, when we exercise, muscles need energy, and $s$ rises. The effect of insulin is magnified by higher $s$, and muscles take up more glucose from the blood.

In contrast, in infection and inflammation, insulin sensitivity drops so that more glucose stays in the blood in order to help the immune system fight pathogens. Insulin sensitivity also drops in pregnancy, diverting glucose to the fetus. In obesity, $s$ drops dramatically, sometimes by a factor of ten. This phenomenon is called **insulin resistance**, since each unit of insulin works much less effectively than in non-resistant people. Insulin resistance is due to factors secreted by fat cells, and to chronic inflammation that often occurs in obesity. For example, in obesity fat cells are overwhelmed and cannot take up excess fatty acids, which accumulates in muscles and in the liver causing signals that increase insulin resistance. Overwhelmed fat cells also secrete inflammatory signals which increase insulin resistance. Insulin resistance is usually coordinated between different tissues- muscle, fat and liver has similar resistance. Insulin resistance, as we will see, is an important factor in T2D.
Despite the fact that people vary in s by as much as ten fold, most people have normal glucose levels and dynamics. For example, the majority of people with obesity, which all have low s, have normal 5mM glucose and GTT dynamics.

If we simulate the minimal model with a 10-fold lower s, we see that steady-state glucose concentration rises by a factor of about 2, and response time also greatly increases (Fig 2.9). Thus, the minimal model cannot explain how most people with obesity have normal glucose. In fact, no model based on the description of the system we studied so far can do so. We need to add another control loop to make glucose dynamics robust to variations in parameters such as s. We will do this in the next chapter.

To see explicitly how sensitive the minimal model is to variations in parameters, we can solve for the steady state glucose:

**Solved exercise 1: Show that the minimal model has steady-state glucose that depends on insulin sensitivity s and all other model parameters**

Steady-state means no change with time, and thus we set the time derivatives to zero: \( dG/dt = 0 \) and \( dI/dt = 0 \). We find from Equation (5), that

\[
(8) \quad s \ I_{st} \ G_{st} = m_{st}
\]

where \( m_{st} \) is the fasting production of glucose from the liver. The subscripts “st” will denote steady-state throughout this course.

Incidentally, this is the origin of the commonly used HOMA-IR equation used in research to estimate insulin sensitivity from steady-state glucose and insulin measurements:

\[
(9) \quad s = m_{st} / I_{st} \ G_{st}
\]

using the estimated parameter \( m_{st} = 22.5 \) whose units assume that glucose is measured in mM and insulin in microU/ml [https://en.wikipedia.org/wiki/Homeostatic_model_assessment].

To find the steady-state solution of the insulin equation Eq. 7, let’s approximate the regulation function \( f (G) \) as \( (G/K)^2 \), as suggested by Topp et. al. (2000). This approximation is derived from the Hill function of Eq 6, with \( n = 2 \) and when \( G \ll K \) which we know is not a bad approximation because otherwise (ie. if \( K \ll G \)) insulin secretion would saturate at 5mM glucose and beta cells would not be able to change their insulin secretion to match blood glucose. Thus, from the insulin Eq 7, solved at steady state by setting with \( dI/dt = 0 \), we find that \( q \ B \ (G_{st} / K)^2 = \gamma I_{st} \). Plugging this into Eq 8, we obtain a steady state glucose level \( G_{st} \) that depends on the cube root of all parameters (the cube root comes from the \( (G/K)^2 \) regulation):

\[
(9) \quad G_{st} = (\gamma K^2 \ m_{st} / s \ q \ B)^{1/3}
\]
Let’s consider the case of insulin resistance due to an 8-fold drop in $s$, keeping all other parameters the same. This will result in a 2-fold rise in $G_{st}$ (because 2 is the cube root of 8, $8=2^3$). We see that $G_{st}$ is not robust to changes in insulin resistance, which means it is sensitive to changes in this parameter, or to any of the other parameters in the model.

Also, we see from Eq 9 that glucose steady state is not robust to any of the model parameters, including $q$, the maximal insulin production rate per beta cell. This parameter can also change as beta cell metabolism depends on many factors and on age. A subtle point is that $q$ also depends on total blood volume, as mentioned above, which dilutes the number of insulin molecules to give rise to insulin concentration. Blood volume grows by 50% in pregnancy, and along childhood growth, and in other physiological conditions. So being robust to $q$ is also biologically important to achieve 5mM strict control.

**Solved exercise 2: Show that half-life of glucose in the blood is also not robust to insulin sensitivity.**

Likewise, the half-life of glucose in the blood is not robust. To see this, let’s recall the removal term of glucose, namely $s I G$. The removal parameter— the factor multiplying $G$ that has units of 1/time, is $a=s I$. The half-life, as discussed in the beginning of the chapter, is therefore $t_{1/2} = \ln(2)/a = \ln(2)/s I$. Let’s consider the case that the system is at steady state, and now a small amount of glucose is added to the blood, that hardly affects insulin concentration. Since at steady state $I = I_{st}$, the half-life is $\ln(2)/s I_{st}$. We can compute $I_{st}$ from Eq. 8 and 9: $I_{st} = (m_{st}^2 q B/s^2 \gamma K^2)^{1/3}$ and thus the half life is $t_{1/2} = \ln(2)/s I_{st} = \ln(2)/(s m_{st}^2 q B/\gamma K^2)^{1/3}$. Therefore, glucose half-life depends inversely on the cube root of insulin sensitivity, $s^{-1/3}$. Half-life doubles if $s$ grows by a factor of 8. In insulin resistance, therefore, the model predicts that glucose is removed more slowly, all things being equal.

Thus, the prose description of the insulin-glucose circuit seems to work qualitatively well. But when we write the equations, we can see that we need additional mechanisms to explain the robustness of glucose concentration and its dynamics with respect to physiological parameters. We need to explain why most people with obesity, pregnancy or athletic lifestyles have very different insulin resistance but normal 5mM glucose and normal dynamics in the glucose tolerance test.

In the next chapter we will see how answering the question of robustness of glucose dynamics leads to general principles for a feedback control in tissues. This new feedback will have unavoidable fragilities that explain why beta cells fail in T2D, as we will see in chapter 2, and why the body attacks its own beta cells in T1D, as well see later on in Part 2 of the course.

See you next week:)  
*deep sigh of relief*
Appendix:

Exactly solvable approximation for response time in the minimal model

\[
\frac{dG}{dt} = m - s I G
\]
\[
\frac{dI}{dt} = qB f(G) - c I
\]

Suppose a big long meal, \( m(t) = m_1 \). Glucose rises and maximizes \( f(G) \) to \( f(G) = 1 \) for enough time that I reach its high steady state

\[ I_1 = qB/c \]

Glucose when the meal ends is at its high level

\[ G_1 = m_1/s \]

Now meal ends and \( m(t) \) drops to its basal level \( m_0 \) (liver glucose production repressed by insulin).

\[
G(t) = G_o + (G_1 - G_o) \exp(-s I_1 t) = G_o + (G_1 - G_o) \exp(-[s \cdot q \cdot B/c] t)
\]

Response time is \( t_{1/2} = \ln(2) \cdot c/sqB \), depends on all parameters

Area under the \( m(t) \) curve in the decline phase is about \( G_1 \cdot t_{1/2} \sim m_1 (c/sqB)^2 \); goes up very high with \( s \) and \( q \).

In the BIG model,

\[
\frac{dB}{dt} = B \mu(G)
\]

\( G_u = G_o \) and hence \( I_u = m_0/s \cdot G_o \) and \( B_u = c \cdot m_0/(s \cdot q \cdot f(G_o)) \)

Response time is \( t_{1/2} = \ln(2) \cdot c/sqB = \ln(2) \cdot G_o \cdot f(G_o)/m_o \) independent on \( s, q, c \)

\[ G_1 = m_1/s \cdot I_1 = m_1 \cdot c/sqB = m_1 \cdot G_o \cdot f(G_o)/m_o \], area under curve independent on \( s \) and \( q \).

Osmosis video on Diabetes Mellitus: [https://www.youtube.com/watch?v=-B-RVybvfU](https://www.youtube.com/watch?v=-B-RVybvfU)

References:

Biological appendix:

Source: https://link.springer.com/referenceworkentry/10.1007%2F978-3-319-45015-5_8

In order to appreciate the multiple pathophysiologic disturbances responsible for the development of impaired glucose metabolism in individuals with type 2 diabetes mellitus (T2DM), a review of the whole body, organ, and cellular mechanisms involved in the maintenance of normal glucose homeostasis in the postabsorptive state (10–12-h overnight fast) and following ingestion of a typical mixed meal is warranted (DeFronzo 1998, 1997, 2009; DeFronzo and Ferrannini 2010). During the sleeping and throughout the postabsorptive state, the great majority of total body glucose disposal takes place in insulin independent tissues, primarily the brain and other neural tissues which account for ~50% of all glucose utilization. Brain glucose utilization is insulin independent and saturates at a plasma glucose concentration of ~40 mg/dl (DeFronzo and Ferrannini 2010; Grill 1990). Since the normal fasting plasma glucose (FPG) concentration is ~70–80 mg/dl, this provides a large window of protection against cerebral neuroglycopenia. During the postabsorptive state, ~25% of glucose disposal takes in the splanchnic area (liver plus gastrointestinal tissues) and is insulin independent. Insulin-dependent tissues, primarily muscle and to a lesser extent adipose tissue, account for the remaining ~25% of glucose utilization. Basal glucose utilization averages ~2.0 mg/kg per min and is precisely matched by the rate of endogenous glucose production. Approximately 85% of endogenous glucose production is contributed by the liver and the remaining ~15% by the kidney. The ratio of insulin to glucagon in the portal circulation is the primary regulator of hepatic glucose production (Cherrington 1999), while in the kidney insulin is primary regulator of renal glucose production (Meyer et al. 1998a). Glucagon has been reported to have no effect on renal glucose production (Stumvoll et al. 1998). Glycogenolysis and gluconeogenesis contribute approximately equally to the basal rate of hepatic glucose production, while gluconeogenesis is responsible for all of renal glucose production (Cherrington 1999; Gerich et al. 2001).

Following ingestion of glucose or a mixed meal, the plasma glucose concentration rises resulting in the stimulation of insulin secretion by the pancreatic beta cells (DeFronzo and Ferrannini 2010; Ferrannini and DeFronzo 2015). The combination of hyperinsulinemia and hyperglycemia (i) stimulates glucose uptake by splanchnic (liver and gut) and peripheral (muscle and adipose) tissues and (ii) suppresses endogenous (hepatic and renal) glucose production (DeFronzo 1998, 1997, 2009; DeFronzo and Ferrannini 2010, 1987; Ferrannini and DeFronzo 2015; DeFronzo et al. 1985, 1981; Ferrannini et al. 1985; Mandarino et al. 2001). Muscle accounts for the majority (~80–85%) of glucose uptake by peripheral tissues, with a small amount (~5%) being disposed of by adipocytes. Although fat accounts for only a small amount of glucose disposal, it contributes to the maintenance of total body glucose homeostasis by regulating the release of free fatty acids (FFA) from stored triglycerides and through the production of adipocytokines that influence insulin sensitivity in muscle and liver (Bays et al. 2004; Groop et al. 1989; Bergman 2000). Lipolysis is highly sensitive to insulin, and the rise in plasma insulin concentration following glucose/meal ingestion results in a decline in plasma FFA concentration (Groop et al. 1989). FFA inhibit glucose uptake in muscle and stimulate hepatic glucose production (Belfort et al. 2005; Bajaj et al. 2005; Groop et al. 1991). As the plasma FFA concentration declines following glucose/meal ingestion, muscle glucose uptake is increased and hepatic glucose production is inhibited. Thus, the
reduction in plasma FFA concentration in response to the increases in plasma insulin and glucose concentrations plays an important role in the maintenance of normal glucose homeostasis (Bays et al. 2004; Groop et al. 1989; Bergman 2000; Belfort et al. 2005).

Glucagon secretion by the alpha cell also plays a central role in the regulation of fasting and postprandial glycemic (Cherrington 1999; Baron et al. 1987). During fasting conditions, approximately half of total hepatic glucose output is dependent upon glucagon, and inhibition of basal glucagon secretion with somatostatin reduces hepatic glucose output and plasma glucose concentration. After a meal glucagon secretion is inhibited by insulin, and the decline in plasma glucagon plays a pivotal role in the suppression of hepatic glucose production and maintenance of normal postprandial glucose tolerance. If, following a meal, glucose enters from both the liver and gastrointestinal tract, postprandial hyperglycemia will ensue. Within the pancreas, approximately 70% of the beta cells are in direct communication with nonbeta cells, including alpha cells, through gap junctions containing connexin proteins (Bosco et al. 2010; Orci et al. 1975; Benninger and Piston 2014). In addition, beta cells can influence alpha cell secretion via intraislet blood flow (Jain and Lammert 2009). Thus, the local paracrine effect of insulin, as well as the rise in circulating plasma insulin concentration, conspires to inhibit glucagon secretion.

Following oral glucose administration, the amount of insulin which is secreted is 2.5–3 fold greater than if glucose were given intravenously to mimic the plasma glucose concentration observed following glucose ingestion. This is referred to as the incretin effect and is related to the release of glucagon-like peptide-1 (GLP-1) from the L cells in the distal small bowel/large intestine and glucose-dependent insulinotropic polypeptide (previously called gastric inhibitory polypeptide) (GIP) from the K cells in the early part of the small intestine (Drucker 2006, 2013; Holst 2007; Nauck and Meier 2016). Collectively, GLP-1 plus GIP account for 60–70% of the insulin that is secreted during a meal. All nutrients (glucose, protein, fat) stimulate GLP-1 and GIP secretion, but glucose is the most potent. GLP-1, but not GIP, also inhibits glucagon secretion, and the decline in plasma glucagon concentration contributes to suppression of hepatic glucose production following meal ingestion. Within minutes after ingestion of a meal, circulating levels of GLP-1 and GIP increase. This occurs long before nutrients can reach the K cells in the duodenum and the L cells in the more distal intestine. This rapid release of GLP-1 and GIP is mediated via neural impulses that are carried to the hypothalamus and back to the intestinal cells via the vagus nerve (Nauch and Meier 2016). GLP-1 and GIP bind to their respective receptors on the β cell, leading to activation of adenyl cyclase and an increase in insulin secretion (Drucker 2006, 2013; Holst 2007; Nauck and Meier 2016). Importantly, the stimulation of insulin secretion by GLP1 and GIP is glucose-dependent; that is, insulin release is augmented in the presence of hyperglycemia and wanes as the blood glucose concentration returns to normoglycemic levels. Similarly, the inhibitory effect of GLP-1 on glucagon secretion wanes as the plasma glucose concentration returns to its baseline level, allowing hepatic glucose production to increase, thereby preventing hypoglycemia.

The route of glucose entry into the body also plays an important role in glucose homeostasis (Cherrington 1999; DeFronzo et al. 1978a; Ferrannini et al. 1980). IV glucose exerts a modest effect to increase splanchnic glucose uptake, and the increase in SGU is directly proportional to
the increase in plasma glucose concentration (DeFronzo et al. 1985). Similarly, intravenous insulin exerts only a small stimulatory effect on splanchnic (liver plus gut) glucose uptake. In contrast, when glucose is ingested, splanchnic glucose uptake increases markedly in direct proportion to the negative hepatic artery-portal vein glucose concentration gradient (Cherrington 1999). As this gradient widens, a neural reflex is activated in which vagal activity is enhanced and sympathetic nerves innervating the liver are inhibited. These neural changes stimulate hepatic glycogen synthase, inhibit glycogen phosphorylase, and augment liver glucose uptake and glycogen formation. Consequently, following oral glucose administration, splanchnic tissues remove ~30–40% of the ingested glucose. This is in marked contrast to IV glucose/insulin administration, where muscle accounts for the majority (~85%) of glucose disposal.

![Plot of insulin secretion rate against the concomitant plasma glucose concentration in subjects with normal glucose tolerance (NGT), impaired glucose tolerance (IGT), and type 2 diabetes (T2D) by quartile of fasting hyperglycemia. The mean slope of the fitting functions measures β-cell glucose sensitivity. (Source: Ferrannini et al., J Clin Endocrinol Metab 90:493–500, 2005)](image-url)